Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
07:00am, Monday, 02'nd Dec 2024
- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalt
2 Dividend Stocks to Buy and Hold Forever
03:45pm, Sunday, 01'st Dec 2024
No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going and
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
01:05pm, Thursday, 28'th Nov 2024
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
Basel, November 27, 2024 – Novartis announced today that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment o
Basel, November 25, 2024 – Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Expositio
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
02:41pm, Friday, 22'nd Nov 2024
NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.
Franklin International Equity Fund Q3 2024 Commentary
04:45am, Friday, 22'nd Nov 2024
Jinda Noipho Performance Data Average Annual Total Returns 4(%) 1 Mth 3 Mths 1 Year 3 Year 5 Year 10 Year Since Inception Inception Date Class C (MUTF:LMGEX) - With Sales Charges a -1.46 4.15 21.61 5.
Novartis: launch of Morphosys drug by could be 2027 or later
03:12am, Thursday, 21'st Nov 2024
Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safet
Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio
02:07am, Thursday, 21'st Nov 2024
The pharma company raised its guidance on revenue growth from its key treatments and expected drug launches, and now anticipates annual currency-adjusted sales to grow by 6% through 2028.
Novartis raises annual sales guidance until 2028
01:15am, Thursday, 21'st Nov 2024
Novartis on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions.
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
01:00am, Thursday, 21'st Nov 2024
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029 Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ pe
Novartis ranks first in 2024 Access to Medicine Index
08:00am, Tuesday, 19'th Nov 2024
Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company's leadership in improving access to medicines around
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
08:00am, Monday, 18'th Nov 2024
Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON , Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative tec
Here's Why Novartis (NVS) is a Strong Value Stock
10:45am, Friday, 15'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
10:35am, Thursday, 14'th Nov 2024
Novartis (NVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
